Cystargamide B, a cyclic lipodepsipeptide with protease inhibitory activity from Streptomyces sp

J Antibiot (Tokyo). 2018 Jul;71(7):662-666. doi: 10.1038/s41429-018-0044-0. Epub 2018 Mar 22.

Abstract

We identified a new cyclic lipodepsipeptide, cystargamide B (1), from the mycelial extract of a Kaempferia galanga rhizome-derived actinomycete strain, Streptomyces sp. PB013. The planar structure was elucidated based on high resolution fast-atom bombardment mass spectrometry (HRFABMS) spectroscopy and one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR) spectroscopic data. The absolute configurations of the constituent amino acids were determined using advanced Marfey's method. Cystargamide B (1) includes rare structural units: a 5-hydroxytryptophan residue and a 2,3-epoxy fatty acid side chain. Notably, cystargamide B (1) inhibited the protease activity of the NS2B/NS3 complex from dengue virus.

MeSH terms

  • Dengue Virus / enzymology
  • Depsipeptides / isolation & purification*
  • Depsipeptides / pharmacology*
  • Magnetic Resonance Spectroscopy
  • Molecular Conformation
  • Protease Inhibitors / isolation & purification*
  • Protease Inhibitors / pharmacology*
  • Rhizome / microbiology
  • Spectrometry, Mass, Fast Atom Bombardment
  • Streptomyces / chemistry*
  • Zingiberaceae / microbiology

Substances

  • Depsipeptides
  • Protease Inhibitors
  • cystargamide b